The company has also filled 10,000 vials of preservative-free Methotrexate Injection, USP, which should be available to clinicians shortly.
A further 10,000 vials have been filled and the company plans to file supply them to the customers by the end of March 2012.
Both forms of Methotrexate Injection are produced by APP at its Melrose Park, Illinois manufacturing facility.
APP president and chief executive officer John Ducker said as soon as the company learned of the shortage of preservative-free Methotrexate, it worked with the FDA.
APP executive vice president and chief commercial officer Scott Meacham said the company is an active member of the Generic Pharmaceutical Associations’ Drug Shortage Task Force.
"APP is working with industry colleagues to draft the Accelerated Recovery Initiative (ARI)," Meacham added.